Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT02432027

Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test

A Single-Center, Randomized, Observer Blind, Vehicle- and Comparator-controlled Trial to Evaluate the Antipsoriatic Efficacy and Safety of Topical Formulations of C-82 in a Psoriasis Plaque Test

Sponsor: Prism Pharma Co., Ltd.

Conditions Psoriasis

Interventions C-82 Topical Gel, 1% C-82 Topical Gel, Placebo Daivonex cream Diprosis gel

Updated 5 times since 2017 Last updated: Aug 16, 2017 Started: Jun 30, 2015 Primary completion: Aug 31, 2015 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02432027, this PHASE1/PHASE2 trial focuses on Psoriasis and remains completed. Sponsored by Prism Pharma Co., Ltd., it has been updated 5 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Prism Pharma Co., Ltd.

Data source: Prism Pharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Schwerin, Germany